Global Roflumilast Patent Report 2016 – Extension and Data Exclusivity Expiry Snapshot – Research and Markets

Need fast access to comprehensive SPC, data exclusivity, and litigation intelligence that’s simple to access and use? Already used by big pharma, biologics manufacturers and their law firms, Patent, Extension and Data Exclusivity Expiry Snapshot saves you days of research and instantly puts you in-the-know.

This report covers:

– International Nonproprietary Name: Roflumilast

– Indications: Treatment and maintenance of severe chronic obstructive pulmonary disease, optionally in combination with bronchodilators and/or corticosteroids

– Innovator:Nycomed (Daxas, Libertek); Merck (Daxas); Forest Res (Daliresp); Tadeka (Daxas)

Examples of information found in this online report include:

– Includes key patent publications for 9 main countries

– Extension and data exclusivity expiry in one simple view

– Expert constraint analysis, commentary, and SPC validity flags

– SPC analyser

– Full consideration of paediatric,orphan and complex data exclusivity

– Patents interpreted and assigned to categories

– Summary of dosage forms, strengths, indications and active ingredient forms of the brand product

– DMF & Paragraph IV filings

– Litigation alerts

– Marketing authorisation holders in selected territories

– Hyper-linking to crucial patent documents and national registries enabling data verification

Insight and understanding for all levels of expertise

– Patents interpreted and assigned to categories

– Expert constraint analysis, commentary, and SPC validity flags

– Flags indicate constraining, difficult or nuisance patents

– Available on a per molecule basis

Save vast amounts of time

– Complete, reliable and verifiable data so you don’t have to fill holes and double check

– Intelligent, friendly design means fewer clicks and quicker understanding

– Hyperlinking to vital patent documentation allows fast analysis and verification

– Add your own notes, save searches and results